These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24714850)

  • 1. Extravasation of Noncytotoxic Drugs: A Review of the Literature.
    Le A; Patel S
    Ann Pharmacother; 2014 Jul; 48(7):870-886. PubMed ID: 24714850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of noncytotoxic extravasation injuries: A focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline.
    Stefanos SS; Kiser TH; MacLaren R; Mueller SW; Reynolds PM
    Pharmacotherapy; 2023 Apr; 43(4):321-337. PubMed ID: 36938775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of extravasation injuries: a focused evaluation of noncytotoxic medications.
    Reynolds PM; MacLaren R; Mueller SW; Fish DN; Kiser TH
    Pharmacotherapy; 2014 Jun; 34(6):617-32. PubMed ID: 24420913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for Management of Noncytotoxic Vesicant Extravasations.
    Ong J; Van Gerpen R
    J Infus Nurs; 2020; 43(6):319-343. PubMed ID: 33141794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extravasation management.
    Schulmeister L
    Semin Oncol Nurs; 2007 Aug; 23(3):184-90. PubMed ID: 17693345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Oncology Nursing Society extravasation guidelines.
    Wengström Y; Margulies A;
    Eur J Oncol Nurs; 2008 Sep; 12(4):357-61. PubMed ID: 18765210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extravasation of Noncytotoxic Drugs.
    David V; Christou N; Etienne P; Almeida M; Roux A; Taibi A; Mathonnet M
    Ann Pharmacother; 2020 Aug; 54(8):804-814. PubMed ID: 32054312
    [No Abstract]   [Full Text] [Related]  

  • 8. Antidotes to vesicant chemotherapy extravasations.
    Dorr RT
    Blood Rev; 1990 Mar; 4(1):41-60. PubMed ID: 2182147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesicant extravasation part II: Evidence-based management and continuing controversies.
    Wickham R; Engelking C; Sauerland C; Corbi D
    Oncol Nurs Forum; 2006 Nov; 33(6):1143-50. PubMed ID: 17149397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Risk of Injury by Extravasation of Hyperosmolar and Vasopressor Agents in a Rat Model.
    Shibata Y; Sagara Y; Yokooji T; Taogoshi T; Tanaka M; Hide M; Matsuo H
    Biol Pharm Bull; 2018; 41(6):951-956. PubMed ID: 29863084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Extravasation of chemotherapeutic agents: prevention and therapy].
    Jordan K; Grothe W; Schmoll HJ
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):33-7. PubMed ID: 15619172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of Skin Injury Risk Caused by Extravasation of Electrolyte Solutions or Infusions in a Rat Model.
    Taogoshi T; Shibata Y; Uno H; Yokooji T; Tanaka M; Hide M; Matsuo H
    Biol Pharm Bull; 2022; 45(9):1254-1258. PubMed ID: 36047193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxanes: vesicants, irritants, or just irritating?
    Barbee MS; Owonikoko TK; Harvey RD
    Ther Adv Med Oncol; 2014 Jan; 6(1):16-20. PubMed ID: 24381657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injury due to extravasation of thiopental and propofol: Risks/effects of local cooling/warming in rats.
    Shibata Y; Yokooji T; Itamura R; Sagara Y; Taogoshi T; Ogawa K; Tanaka M; Hide M; Kihira K; Matsuo H
    Biochem Biophys Rep; 2016 Dec; 8():207-211. PubMed ID: 28955958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of anthracycline extravasation injuries.
    Reeves D
    Ann Pharmacother; 2007 Jul; 41(7):1238-42. PubMed ID: 17550954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Describing Intravenous Extravasation in Children (DIVE Study).
    Paquette V; McGloin R; Northway T; Dezorzi P; Singh A; Carr R
    Can J Hosp Pharm; 2011 Sep; 64(5):340-5. PubMed ID: 22479086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an Evidence-Based List of Noncytotoxic Vesicant Medications and Solutions.
    Gorski LA; Stranz M; Cook LS; Joseph JM; Kokotis K; Sabatino-Holmes P; Van Gosen L;
    J Infus Nurs; 2017; 40(1):26-40. PubMed ID: 28030480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronidase for the management of dextrose extravasation.
    Wiegand R; Brown J
    Am J Emerg Med; 2010 Feb; 28(2):257.e1-2. PubMed ID: 20159411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of anticancer agent extravasation: A single institutional guideline.
    Kimmel J; Fleming P; Cuellar S; Anderson J; Haaf CM
    J Oncol Pharm Pract; 2018 Mar; 24(2):129-138. PubMed ID: 29284352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of highly concentrated dextrose solution (50% dextrose) extravasation and treatment--a clinical report.
    Lawson SL; Brady W; Mahmoud A
    Am J Emerg Med; 2013 May; 31(5):886.e3-5. PubMed ID: 23602753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.